TEAD2, a transcriptional enhancer factor, contributes to EMT in breast cancer and pancreatic adenocarcinoma (PDAC) by directing its co-factor YAP1 to the nucleus (32, 33). Here, TEAD2 is linked to pancreatic adenocarcinoma.